Mammary epithelia are composed of luminal and myoepithelial/basal cells whose neoplastic transformations lead to distinct types of breast cancers with diverse clinical features. We report that mice deficient for the CDK4/6 inhibitor p18
INTRODUCTION
Mammary epithelia are composed of two major epithelial cell types: ductal and alveolar luminal cells, constituting the inner layer of ducts and the lobuloalveolar units, respectively; and a basal layer of myoepithelial cells surrounding the luminal cells. Both epithelial cell types are believed to originate from a common multipotential stem cell Stingl et al., 2006) . Histopathologically, breast cancer can be divided into two major types: luminal tumors that account for the majority of breast cancer cases (70%-80%) and are typically estrogen receptor (ER) positive; and basal-like breast cancers that have high histological grades and mitotic indices, are ER negative, and are associated with a poor prognosis (Althuis et al., 2004) .
Gene expression profiling analyses have further categorized human breast tumors into several intrinsic subtypes that correlate with tumor biology and are prognostic and predictive for patient outcomes (Hu et al., 2006; Perou et al., 2000; Sorlie et al., 2003) . The genetic, cellular, and biochemical mechanisms controlling lineage commitment and maturation in the mammary gland bear clinical significance, because different types of breast tumors possess different outcomes and are diverse in their responsiveness to treatment but remain to be defined. The cellular origin of breast cancer and how its various subtypes arise are not fully understood, and appropriate animal models for studying this disease are still needed. p18 Ink4c (referred to as p18 hereafter) is a member of the mammalian INK4 family that inhibits CDK4 and CDK6, whose
SIGNIFICANCE
Breast cancer is heterogenous with tumors pathologically distinct and diverse in their responsiveness to treatment. We show that the CDK inhibitor p18 INK4c gene is repressed by GATA3, a transcription factor specifying mammary luminal cell fate, and that low INK4C and high GATA3 expressions are associated with human luminal A type tumors and with better patient survival. p18
Ink4c
-null mice have an expanded luminal progenitors at a young age and throughout life and develop ER + luminal tumors at high penetrance. These results identify the escape of luminal progenitors from quiescence as a rate-limiting step for initiation of mammary luminal tumors. The Ink4c-null mouse represents a unique model for study and for developing therapeutic strategies to treat luminal tumors.
activation by mitogen-induced D-type cyclins leads to phosphorylation and functional inactivation of RB, p107, and p130. Functional inactivation of this pathway is a common event in the development of most types of cancer (Sherr, 1996) . p18 is a haploinsufficient tumor suppressor in mice whose deletion promotes the development of various tumors, including lymphoma, medulloblastoma, glioblastoma, and tumors of neuroendocrine organs, lung, and prostate (Bai et al., 2003 (Bai et al., , 2006 Franklin et al., 1998; Latres et al., 2000; Pei et al., 2007; Uziel et al., 2005) . Deletion or reduced expression of the p18 gene has also been observed at high frequency in different types of human cancer.
Three lines of evidence suggest a potential function of p18 in suppressing mammary tumors. First, the cyclin D1 gene, located on human chromosome 11q13 and a functional antagonist of p18, is amplified in a substantial portion of human breast cancer (reviewed in Ormandy et al., 2003) . Transgenic expression of MMTV (mouse mammary tumor virus) cyclin D1 promotes mammary tumor development (Wang et al., 1994) . Second, deletion in mice of cyclin D1 or CDK4, the target of p18, conversely retards mammary gland development and prevents MMTV-oncogene induced mammary cancer (Fantl et al., 1995; Sicinski et al., 1995; Yu et al., 2001 Yu et al., , 2006 . Lastly, female p18 null mice (in BL/6 background) display mammary gland hyperplasia with ectasia in their galactophor ducts (Latres et al., 2000 and our unpublished observation) . We carried out this study to determine the function and mechanism of p18 in suppressing mammary tumorigenesis.
RESULTS

p18
À/À Mice Develop Predominantly
ERa-Positive Luminal Mammary Tumors
To determine the function of p18 in mammary tumor suppression, we introduced p18 À/À into the Balb/c strain, which is known to be susceptible to mammary tumor development and is widely used for such study, by backcross (Ponnaiya et al., 1997; Ullrich et al., 1996) . The tumor spectrum, incidence, and onset time of many tissues, including pituitary, thyroid, testis, pancreas, and lung, increased in the Balb/c background compared with the BL/6 background (data not shown). The most striking phenotype in Balb/c-p18 mice was mammary gland tumors, and mammary tumor-free survival was reduced from a mean age of 27.3 months in wildtype (WT) mice, to 20.9 months in p18 +/À and 15.4 months in p18 À/À mice ( Figure 1A ).
Mammary tumors developed in Balb/c-p18 À/À mice at a very high incidence, including 23% (n = 13) of females examined less than 1 year of age and 88% (n = 17, including 1 male) between 1 year and 20 months ( Figure 1B ). Most mammary tumors from p18 À/À and p18 +/À mice were preinvasive carcinomas, such as ductal carcinoma in situ (DCIS), and exhibited papillary, cribriform, and cystic characteristics with low and intermediate nuclear grades (Figure 1C ). Only 2 of 18 (11%) p18 À/À mammary tumors were invasive ductal carcinoma (IDC), and one of them metastasized to the lung. Normal breast ducts contain two types of epithelial cells: luminal cells that are round or polygonal and line the inner ductal lumen, and basal/myoepithelial cells that are elongated and contact the basement membrane but never contact the lumen. Luminal and basal/myoepithelial cells can also be distinguished by their different cytokeratin (CK) expression patterns. The majority of luminal cells express CK7, 8, 18, 19, and 20 , whereas basal/myoepithelial cells typically express CK5, 13, 14, and 17. p18 À/À mammary carcinomas, most of which retained an organized gland and duct structure, stained strongly and uniformly for CK8 but not CK5, indicating that they predominantly contain luminal epithelial cells ( Figure 1D ). Most (13 of 15, 87%) p18 À/À mammary tumors examined were positive for ERa. The percentages of ERa-positive cells varied among individual p18 À/À mammary tumors, from as low as 2%-5% in six tumors, to more than 20% in the other nine, indicating heterogeneity and potentially different stages of tumor development. ERa-positive cells were frequently detected in p18 À/À mammary tumors, where tumors were well differentiated and still retained an overall normal architecture of mammary glands ( Figure 1E , left and middle), or when poorly differentiated tumors were investigated ( Figure 1E , right). When compared with 13 different murine mammary tumor models (Herschkowitz et al., 2007) , p18 À/À mammary tumors express the highest level of ER (data not shown). It should be pointed out, however, that most mammary tumors developed in p18 À/À mice are DCIS, with only 11% IDC or metastatic tumors, whereas mammary tumors developed in other murine models are mostly invasive carcinoma. It remains to be determined whether the difference in ER expression between p18 À/À tumors and tumors of 13 other models reflects different stages in tumor progression or inherent differences in tumor biology. Together, these results suggest that p18 plays an important role to suppress the development of ERa-positive luminal mammary tumors in mice.
p18 Deficiency Stimulates Proliferation and Rb Protein Phosphorylation in Luminal Cells
We determined cell proliferation in mammary tumors developed in p18 À/À mice (>14 months of age) by examining both the proliferation marker Ki67 (Figure 2A ) and the mitotic marker Figure 2C ). Finally, we directly examined the status of Ser608 phosphorylation of Rb protein, the site that is preferentially phosphorylated by p18's targets CDK4 and CDK6 (Schmitz et al., 2004; Zarkowska et al., 1997) . A visible and consistent increase of pRb-Ser608 phosphorylation, both in the intensity and number of positive cells, was seen in normal p18 À/À mammary epithelia (11.2 ± 1.8% in WT to 23.5 ± 3.8% in p18
) and p18 À/À tumors (34.5 ± 5.7%, Figure 2D ), supporting the activation of CDK4 and/or CDK6. Most Rb-Ser608-positive cells were luminal cells. Taken together, these results demonstrate that p18 deficiency stimulates CDK4 and/or CDK6 activity toward the Rb protein in luminal epithelial cells, increasing their proliferation in a cell autonomous manner at an early age before the development of any detectable preneoplastic lesion. Loss of p18 also maintains luminal cells at a hyperproliferative state throughout adulthood, during which time p18 À/À luminal cells progressively develop from hyperplasia to tumor.
Loss of p18 Increases Label-Retaining Luminal Epithelial Cells
We explored the possibility that p18 loss stimulates mammary stem and/or luminal progenitor cell proliferation. One unique feature of stem/progenitor cells is their slow rate of proliferation. As a result, the BrdU label incorporated during a long period of pulse labeling can be retained after a long period of chase by the stem/progenitor cells but is continuously diluted in other somatic cells by each cell cycle. Label-retaining cells (LRCs) have been demonstrated to be enriched in both mammary stem and progenitor cells Smith, 2005; Welm et al., 2002) . We injected BrdU into pubertal littermates twice a day consecutively for 7 days and determined the LRCs after short (1 day) and long (37 days) chase. At day 1 of chase, more than half of the epithelial cells were BrdU positive in both WT (51.7% ± 6.8%) and p18 À/À mammaries (55.3% ± 8.1%) ( Figure 3A ). After 37 days of chase, BrdU-positive LRCs were only sparsely detected in the WT mammaries but were notably increased in p18 À/À mammaries ( Figure 3B ). Microscopic examination of 12 mammary glands from three mice of each genotype revealed a 1.6-fold increase of LRCs in p18 À/À mammary glands (14.5% ± 1.8%) over WT glands (9.1% ± 1.3%). Most LRCs in both WT and p18 À/À mammaries were round or polygonal, located in the inner layer of the duct, and made contact with the ductal lumen, indicative of luminal epithelium.
To confirm this, we stained mammary sections with CK8 and CK5 and determined that, indeed, most WT (7.3% ± 1.4% of total mammary epithelium and 80.2% of total LRC) and p18 À/À LRCs (12.04% ± 1.7% of total mammary epithelium and 83% of total LRC) were positive for CK8 ( Figure 3B ). Notably, the CK8-positive LRCs, which are likely enriched for luminal progenitor cells, were increased by 1.7-fold by p18 loss, from 7.3% of total epithelial cells in WT mammaries to 12% in p18 À/À mammaries ( Figure 3B ).
Loss of p18 Increases Cells with Morphologic Features of Luminal Progenitors
Previously, Smith and colleagues combined light and electronic microscopic analyses of the mammaries from different mammals and defined five histologically distinct epithelial cell populations based on the cell size and nuclear and cytoplasmic staining characteristics: small light cell (SLC), undifferentiated large light cell (ULLC), differentiated large light cell (DLLC), large dark cell (LDC), and myoepithelial cell (MYO) (Chepko et al., 2005; Smith and Medina, 1988) . Both small and large light cells appear to be division competent, based on their condensed chromosomes and capability to undergo mitosis in explant culture. Combined with the characterization of the cytoplasmic organelle differentiation and localization in the glands, these features led to the proposal that SLCs represent a population enriched for mammary stem cells that divide and differentiate progressively into ULLC, likely corresponding to the luminal progenitors, and then to DLLC, before terminal differentiation into a bulk population of mature luminal cells (LDCs).
To determine the division competency of these structurally defined cell populations and their label-retaining ability, we took immunostained sections from the label retaining assay (37 day chase), restained them with H&E, and matched 793 cells from WT and 946 cells from p18 À/À mammaries from two stainings by side-by-side microscopic comparison ( Figure 3C and Table S1 available online). Of these matched cells, 70 from WT and 150 from p18 À/À mammaries were LRCs, and close to half (44% in WT and 48% in p18 À/À mammary, respectively) corresponded to ULLCs. The remaining LRCs were similarly distributed among SLCs, DLLCs, LDCs, and MYOs (Table S1 ). This result indicates that ULLCs represent the majority of LRCs, providing functional support to the histologically defined notion
Cancer Cell
A Mouse Model for ER+ Luminal Breast Cancer that ULLCs represent a progenitor-enriched mammary epithelial cell population. We next microscopically examined more than 20 ducts and lobules from each animal of both genotypes between 2 and 3 months of age, and counted at least three lobules and one duct per animal ( Figure S1 ). Of five major populations, the ULLC population was significantly increased from 16.5% in ducts and 19% in lobules of WT mammaries, to 28.1% and 25% in p18 À/À ducts and lobules, respectively, and led to a 50% overall increase of ULLCs from WT (17.6%) to p18 À/À (26.5%) mammaries ( Figure 3D , and Figure S1 ). The SLC population was very small (less than 3%) and partially overlapped with myoepithelial cells in their localization, making it difficult to determine whether p18 deletion also affects the size of the putative mammary stem cell population. There is no significant difference in relative distribution of the other three populations, as well as cells of unknown (UK) origin, between WT and p18 À/À mammaries ( Figure S1 ). These results demonstrate that luminal progenitor-enriched ULLCs are the major cell population affected by the loss of p18 at an early age, before tumor development. + population, which is enriched with progenitors and has a luminal cell fate under lactogenic condition (Asselin-Labat et al., 2007; Shackleton et al., 2006; Sleeman et al., 2007) , was increased by 1.5-fold in p18 À/À mammaries compared with WT littermates in Balb/C (42.3 ± 2.5% versus 27.9 ± 3.7%, Figure 4A ) and 1.4-fold in BL/6 (51% versus 35.9%, Figure S2B ) backgrounds at pubertal age (6-8 weeks 
. Loss of p18 Increases Label-Retaining Luminal Epithelial Cells and Cells with Morphologic Features of Luminal Progenitors
(A and B) One-month-old littermate mice were injected intraperitoneally with BrdU twice a day for 7 consecutive days, followed by chase for 1 (A) or 37 days (B) before death. Mammaries were dissected and stained with antibodies to BrdU, CK5, and CK8. The percentage of BrdU-positive cells were calculated as described in Experimental Procedures. Results represent the mean ± SD of three animals per group. (C) After immunofluorescence staining and photographing of sections from the label retaining assay (37 days chase, top panels), the identical section was restained with H&E. Matched cells between two stainings were identified microscopically and label-retaining small light cells (SLCs) and undifferentiated large light cells (ULLCs) were counted (indicated by red and yellow arrows, respectively, bottom panels). Lower-magnification pictures for these paired stainings are shown in (B). Three additional types of histological distinct cell types-differentiated large light cells (DLLCs), large dark cells (LDCs), and myoepithelial cells (MYOs)-were also identified and quantified (see Table S1 ).
(D) Littermate WT or p18 À/À mice at 2-3 months of age were dissected and stained with H&E. SLCs and ULLCs are indicated by red and yellow arrows, respectively. A total of 400-600 ductal and lobular cells from each genotype were counted, and the number and percentage of SLCs and ULLCs are presented. Three other histological types (DLLCs, LDCs, and MYOs) were also identified and quantified ( Figure S1 ).
(42.7 ± 4.0% versus 34.1 ± 2.6%, Figure 4A ), and remained high late in life in p18 À/À mice, 48.3% at 9 months of age and 37.8%
(in hyperplasic tissues) or 42.1% (in tumorigenic tissues) at 14 months of age, and both were higher than WT littermates (41% and 34% at 9 and 14 months of age, respectively). These data suggest that p18 loss results in a continuous increase in the luminal progenitor-enriched CD29 lo CD24 + cell population during aging and development.
CD49f (a6 integrin) is expressed in human mammary colonyforming cells (Ma-CFC) enriched for luminal progenitor cells and has also been used in combination with CD24 to identify mouse Ma-CFCs and stem cells (Stingl et al., 2001 . After exclusion of lymphocytes and dead, hematopoietic, and endothelial cells, we determined that the CD24 high CD49f low population was significantly increased in p18 À/À mammaries compared with WT littermates by 1.8-fold in Balb/c (6 weeks, 7.9% versus 4.2%, Figure 4B ) and 1.7-fold in BL6 (12 weeks, 6.6% versus 3.8%, Figure S2D ) backgrounds. The CD24 high CD49f high population enriched for mammary stem cells, however, did not appear to be significantly affected by p18 loss (3.6% versus 3.2%, Figure 4B ).
The CD24
high CD49f low population in p18 À/À mammary mice also remained higher at 11 months of age than in WT littermate mammaries (5.5% versus 4.0%, Figure S2E (Sleeman et al., 2006 (Sleeman et al., , 2007 . Consistent with the expansion of the CD29 lo CD24 + cell population, the CD24 + Sca1
À population was also higher in p18 À/À mice than in littermate WT mice at postpubertal age (28.3% versus23.3%) and maintained at a higher level later in life (59% in p18 À/À versus 50% in WT mice at 9 months of age and 57% in p18 À/À versus 41.7% in p18 +/À mice at 14.5 months of age) ( Figure 4C Figure 4D ), providing further evidence that p18 loss initiates the expansion of a luminal progenitor-enriched cell population.
p18 Constrains Luminal Progenitor Cell Proliferation in a Cell Autonomous Manner
We next determined the function of p18 in constraining luminal progenitor cell proliferation using three different in vitro systems: 3D Matrigel, mammosphere, and colony-formation assays. The Matrigel assay showed that mammary cells derived from p18
mice exhibited a substantial increase of proliferation and that the majority of BrdU-positive cells were luminal ( Figure 5A ), demonstrating that the increased proliferation of luminal cells in p18
mice is cell autonomous. Mammary stem/progenitors propagated in nonadherent culture in vitro form mammospheres and can differentiate into both luminal and basal/myoepithelial lineages (Dontu et al., 2003) . Cells derived from p18 À/À mammaries showed an increase in primary mammosphere-forming activity (32.8 ± 5.1 spheres per 20,000 cells) than WT cells (26.3 ± 3.4 spheres per 20,000 cells; p = 0.027, paired t test, Figure 5B ), indicating increased stem or progenitor cell function resulting from p18 loss. Most WT spheres were 70-100 mm and 10%-20% were larger than 100 mm, whereas most p18 À/À spheres were 80-120 mm in size and 10%-20% spheres were larger than 120 mm ( Figure 5B ). The average p18 À/À sphere (118 ± 38 mm) was significantly larger than the average WT sphere (92 ± 24 mm, p = 0.017, paired t test, Figure 5B ), further supporting the conclusion that p18 loss increases the proliferative potential of mammary progenitor cells. To examine their differentiation potential, we induced individual mammospheres to differentiate. After 4 days of culture in a gelatin-coated dish, most cells in the spheres were attached, differentiated, and migrated out of the center. Immunostaining identified CK8 + and CK5 + cells in both WT and p18 À/À spheres ( Figure S3 ), confirming that the spheres were capable of differentiating into both luminal and basal/ myoepithelial lineages and that p18 deficiency did not affect the differentiation potential of the mammosphere.
We then compared the colony-forming capacity of WT and p18 À/À mammary epithelial cells (MECs) in Matrigel and scored both spherical and flat colonies. To score spherical colonies, we divided them into > 50 mm and > 100 mm groups and found that p18 À/À MECs formed more spherical colonies in both groups, averaging 10.8 colonies > 100 mm or 9.5 colonies > 50 mm per 1000 MECs seeded, compared with WT or heterozygous MECs that formed on average 6.8 colonies > 100 mm or 4.5 colonies > 50 mm per 1,000 MECs seeded ( Figure 5C ). The p18
MECs also appeared to form more flat colonies in both size groups, but the limited number of flat colonies formed by both WT and p18 À/À MECs prevented us from making a statistically significant determination ( Figure 5C ). Because we used MECs in these FACS and colony-formation assays, we cannot exclude the possibility that p18 might also have a function in regulating stroma cells in vivo, which could contribute to the control of luminal progenitor cell expansion. Almost all spherical colonies generated from either WT or p18 À/À MECs, including both acini with or without lumen, stained strongly for CK8, with varying degrees of CK5 staining ( Figure S4A ). Staining of colonies after dissolving Matrigel revealed two distinct groups of colonies: one containing cells in the center that were strongly stained for CK8 and a few outer layer cells that were stained positively for CK5 ( Figure S4B , left panels); and one comprised uniformly of CK8 + cells throughout the colony (right panels).
To obtain a quantitative assessment, we generated more colonies by seeding a high density of unsorted mammary cells on Matrigel (20-fold more than clonal density). Flat colonies were difficult to identify accurately due to their high density and were not counted. p18 À/À mammary cells formed significantly more spherical colonies in both > 50 mm and > 100 mm size groups and slightly more colonies larger than 200 mm compared with WT littermate mammary cells ( Figure S4C ). Most spherical colonies stained strongly for CK8 with varying degrees of CK5 staining. Considering that serum-free culture conditions favor luminal cell proliferation, which might cause an underestimation of the myoepithelial cells, we divided the spherical colonies into two groups: ''basal colonies'' (CK8+ and > 50% CK5+ cells) and ''luminal colonies'' (CK8+ and < 50% CK5+ cells) ( Figure 5D ). Microscopic examination demonstrated that p18 À/À mammary cells generated 1.6-fold more luminal colonies (377 ± 50.3 per 20,000 cell seeded) than did WT mammary cells (232 ± 30.1 per 20,000 cell seeded, Figure 5D ). p18 À/À mammary cells generated slightly more CK5+ cell enriched basal-like colonies (104 ± 14.7 per 20,000 cells seeded) than the WT MECs (87 ± 17.3 per 20,000 cells seeded), but the increase was not statistically significant (p = 0.27, Figure 5D ). This result supports a unique function of p18 in luminal progenitor proliferation and differentiation.
p18 and GATA3 Expression Levels Are Inversely Related in Human Luminal A Breast Tumors To determine whether our mouse genetic analysis models human breast cancers, we queried the gene expression data of the Netherlands Cancer Institute 295 (NKI295) breast cancer patient sample set (van de Vijver et al., 2002) . The 295 patients were split 50/50 into a ''high'' and ''low'' expression group for each analyzed gene and the distribution of 'high' versus 'low' expression of each gene was determined relative to five intrinsic tumor subtypes: basal-like, Her2+/ERaÀ, luminal A, luminal B, and normal-like as assigned . Using multiple statistical tests, we determined that p18 mRNA expression levels were highly correlated with the breast tumor intrinsic subtype (chi-square p < 0.0001; Figure 6A and Figure 6A and Table S2 ). An inverse correlation between p18 and RB1 expression is consistent with the notion that p18, among four INK4 genes, is the major upstream activator of RB1, and its decrease might relieve selection pressure to decrease or mutate RB1 during tumorigenesis in mammary luminal cells. GATA3, a member of the GATA family of zinc-finger transcriptional factors, was recently identified as essential for the differentiation and maintenance of luminal cell fate and thus for mammary-gland morphogenesis. Restoration of GATA3 in late carcinomas from MMTV-PyMT mice induced tumor differentiation and suppressed tumor dissemination (Kouros-Mehr et al., 2008) . Conspicuously, the expression of GATA3 is high in luminal A and low to absent in basal-like tumors, thus exhibiting an inverse correlation with p18 ( Figure 6A and Table S2 ). Scatter plot analysis further confirmed the inverse correlation between GATA3 and p18 mRNA levels in breast cancer patients from the NKI patient series (correlation coefficient = À0.379, Figure 6B ). This finding suggests the possibility of negative regulation of p18 by GATA3 (see below).
p18 and GATA3 Expression Levels Predict Human Breast Cancer Patient Outcomes
We next examined whether the levels of p18 expression are related to patient outcomes and included all CDK inhibitor genes in the analysis to explore the specificity. Kaplan-Meier analysis of overall survival revealed that ''high'' versus ''low Figure 6C ). Identical results were obtained for relapse-free survival ( Figure S5 ). The statistically significant value of p18 levels in predicting patient outcome is consistent with, and can be explained by, the correlation between low p18 expression and luminal A subtype tumors exhibiting a better outcome (Hu et al., 2006) . The profiling analyses linking the expression of INK4 and RB1 genes with patient outcomes also suggest how an impairment of the RB pathway might clinically predict, and mechanically influence, patient outcomes. A reduction of RB1 level, among all genes acting on the RB pathway, would be most direct and effective in diminishing the activity of the RB pathway and promoting cell proliferation, and is therefore linked with, or leads to, a more malignant phenotype (i.e., basal-like tumors), whereas a reduction of its individual upstream activators, such as p18
INK4C
, is less potent in promoting cell division and is linked with less aggressive tumors (luminal A tumors). Notably, contrary to p18 expression, high GATA3 expression predicts a better patient outcome, thus showing that human luminal A tumors are characterized by high GATA3, high RB1, and low p18.
GATA-3 Negatively Regulates p18 Gene Expression
Prompted by the inverse correlation between p18 and GATA3 expression in human luminal A breast cancer patients, and the Figure 7A ). To directly determine whether Gata3 negatively regulates p18 in mammary epithelium, we first determined the p18 protein level in Gata3-deficient mouse mammary tissue. Specific deletion/ reduction of Gata3 in the mammary gland was achieved by pregnancy of Gata3 f/f ;WAP-cre dams and resulted in a robust increase of p18 protein ( Figure 7B) . Likewise, the knocking down of GATA3 expression in human MCF-7 and 293T cells by two different siRNA oligonucleotide duplexes resulted in increased p18 mRNA and protein levels ( Figures 7C and 7D) . Conversely, overexpression of GATA3 in MCF-10A cells inhibited p18 mRNA expression ( Figure 7E ) and increased cell proliferation, as determined by BrdU incorporation ( Figure 7F ). We also examined Gata3 expression both in vivo in animals at different ages and in vitro in acini-cultured in 3D Matrigel using mammary cells. Gata3 expression was readily detected, but no discernible difference in Gata3 expression was detected between WT and p18 À/À mammary epithelial cells (data not shown). Examination of the p18 promoter reveals several GATA3 consensus sites, including a 40-bp region containing ten GATA3 sequences in tandem located 5.3 kb upstream of the translational initiation ATG codon ( Figure 7G ). To determine if GATA3 directly binds to the p18 locus, we analyzed 6.6 kb upstream and 2.3 kb downstream of the start codon of the human p18 gene by chromatin-immunoprecipitation (ChIP) assay using 33 pairs of primers. Six of 33 amplicons, four upstream (a, b, c, and d in Figure 7G ) and two downstream of the start codon (h and i in Figure 7G ), were specifically enriched in the GATA3 immunoprecipitation ( Figure 7G ). Except for amplicon h, all positive amplicons contain at least one putative GATA3 binding site (data not shown), including one that contains ten GATA3 repeats. Together, these results demonstrate that GATA3 binds to the p18 gene and negatively regulates its transcription.
DISCUSSION
Balb/c-p18 Mouse as a Model for ER + Luminal Tumors
In this study, we report that nearly 90% of female p18-null mice in the Balb/c background spontaneously developed mammary tumors with a median tumor-free survival time of 14 months.
To the best of our knowledge, Balb/c-p18 mice develop mammary tumors at the highest rate among all mutant mice with germline mutations. Our findings support the rate-limiting function of INK4-cyclin Ds-CDK4/6 in suppressing mammary tumorigenesis.
The results presented here also suggest the existence of a genetic modifier(s) in Balb/c mice that interacts with p18 deficiency epistatically to promote tumorigenesis. The possibility of p16
Ink4a , a tumor suppressor that sustained two allelic variations in Balb/c affecting its inhibitory function toward CDK4 (Zhang et al., 1998) , has been ruled out by our observation that p16
À/À in CJ57BL/6 background did not develop mammary tumor at an elevated rate (Ramsey et al., 2007) Figure 7H ). We further suggest that GATA3 promotes the differentiation of mammary stem cells along the luminal lineage through a network of transcription regulation that, on one hand, represses p18 expression to allow the expansion of either luminal progenitors or transit cells of luminal lineage and, on the other hand, activates the expression of genes such as FOXA1 and ERa to induce and maintain the differentiation of mature luminal cells. Further investigations are necessary to determine the factor that trans-activates and/ or maintains p18 expression in luminal progenitors. Loss of Gata3 would result in an accumulation of p18 in the luminal progenitor cells, blocking them from entering an active cell cycle and undergoing subsequent differentiation. Loss of p18, although stimulating the proliferation of luminal progenitor cells and initiating luminal tumorigenesis, would not significantly impair the differentiation of luminal lineage in the presence of normal GATA3 function. Our study also provides a plausible molecular explanation underlying the pathological association and prognostic feature of GATA3. A high level of GATA3, which has been associated with less aggressive lower-grade cancers (Mehra et al., 2005; Sorlie et al., 2003; van de Rijn et al., 2002) , would suppress p18 expression, and a decreased p18 level would favor the development of luminal type breast cancers that have a better outcome for patients.
p18 and p16 May Collaboratively Constrain Stem and Progenitor Cell Proliferation Genetic studies have recently linked the function of p16 with the control of stem and progenitor cells during aging in neuronal, hematopoietic, and pancreatic lineages (Janzen et al., 2006; Krishnamurthy et al., 2006; Molofsky et al., 2006) . These genetic analyses, combined with three lines of evidence from biochemical properties, structural analyses, and the patterns of gene expression, support a model that p16 and p18 collaboratively control stem and progenitor cell cycles. First, rapid turnover of the p21 family of CDK inhibitors and intrinsic stability of INK4 proteins make p21 and INK4 family proteins more suitable for inducing and maintaining a transient and stable cell cycle arrest, respectively. Second, individual INK4 proteins bind to CDK4 and CDK6 with similar affinity. As a result, the activity of CDK4/6 in a given cell is determined by the total concentration of all INK4 combined, rather than individual INK4, making them functionally related and collaborative. Third, p18 is expressed early and sustains a high level throughout life in many adult tissues, whereas the expression of p16 is undetectable in young tissues and is induced during aging (Krishnamurthy et al., 2004; Zindy et al., 1997) . These observations led us to propose that p18 and p16 collaboratively constrain stem cell self-renewal and progenitor cell proliferation, with p18 playing a major role in maintaining the homeostasis of stem/progenitor cells from early embryogenesis throughout adulthood and p16 in limiting stem/ progenitor cell function during aging.
EXPERIMENTAL PROCEDURES
Mice, Histopathology, and Immunohistochemistry The generation and genotyping of p18 and floxed Gata3 mice have been described previously (Franklin et al., 1998; Pai et al., 2003) . p18 mutant mice in BL/6 background were backcrossed for seven generations with BALB/c mice before used for this study as Balb/c-p18 mutant mice. Tissues of most organs were removed, fixed in 10% neutral buffered formalin, and examined histologically by two pathologists after H&E staining. Immunohistochemistry and primary antibodies were as described previously (Bai et al., 2003) . The IACUC (Institutional Animal Care and Use Committee) at UNC approved all procedures.
Morphologic Characterization of Mammary Epithelium
To examine and quantify small light cell (SLC), undifferentiated large light cell (ULLC), differentiated large light cell (DLLC), large dark cell (LDC), and myoepithelial cell (MYO), we followed criteria defined by Smith and colleagues (Chepko et al., 2005; Smith and Medina, 1988) . Cells that could not be clearly defined were categorized as unknown (UK). Three pairs of WT or p18 À/À mice at 2 to 3 months of age were dissected and stained with H&E. All sections were read by two different pathologists (X-H.P. and F.B.). Only sections containing large amounts of epithelium of sufficient quality for counting were selected. Epithelial structures were classified as ducts when they were singular elements associated with no other epithelial structures. They were classified as lobules if they appeared clustered with other small, round epithelial structures or if there were small, round structures that budded from a larger, longitudinally sectioned duct. Cells in terminal end buds were also included in the lobule count.
In Vivo BrdU Labeling Assay For short-term in vivo BrdU labeling analysis, mice were injected with 1 ml per 100 g body weight BrdU cell proliferation labeling reagent (Amersham Bioscience, Little Chalfond, UK) 1 hr before they were killed. Tissues were immunostained with anti-BrdU antibody (Abcam, Cambridge, MA). To determine label retaining cells (LRCs), littermate mice at 1 month of age were injected intraperitoneally with BrdU (50 mg/kg) twice a day for 7 consecutive days followed by chase for 1 day or 37 days before death. Four-micrometer mammary sections were immunostained with antibodies against BrdU, CK5, and CK8. When counting LRCs, only sections containing a large amount of mammary epithelium of sufficient quality were selected, and only confirmed BrdU-positive cells in the duct were counted. Parallel staining of the serial sections for CK8, BrdU, and DAPI was performed to calculate the percentage of CK8 + BrdU + cells in DAPI + mammary epithelium.
Four mammary glands (the fourth and fifth pairs) from each mouse were examined, and at least 600 cells per mammary (more than 2400 epithelial cells per mouse) were counted in the parallel staining of serial sections. The average percentages of BrdU + cells were calculated from three WT and three p18-null mice, respectively.
Patients and Gene-Expression Data Set and Statistical Analyses
We used a data set of breast cancer samples from 295 women (van de Vijver et al., 2002) . Patients were dichotomized into two groups as above or below median for each gene's expression value (2 based log ratio of red channel intensity and green channel intensity). Kaplan-Meier survival plots were performed for relapse-free survival and Overall survival. Cox-Mantel log-rank tests were applied to compare the survival differences and obtained p values, using WinSTAT for Excel (R. Fitch Software). We then compared the two groups of patients for each gene versus five breast cancer subtypes (Hu et al., 2006; Sorlie et al., 2003) using two-way contingency-table analyses and SAS software (Cary, NC). All of the statistical analyses were performed with StatsDirect 2.4.3 software (StatsDirect Statistical Software). The survival rate was calculated by the Kaplan-Meier method. Detailed descriptions for the mammary cell preparation, FACS analysis, cell sorting, 3D Matrigel assay, colony-formation assay, mammosphere assay, cell culture, retroviral infection, RNA interference, western blot, quantitative realtime polymerase chain reaction, and ChIP assay are available in Supplemental Experimental Procedures.
SUPPLEMENTAL DATA
The Supplemental Data include five figures, two tables, and Supplemental Experimental Procedures and can be found with this article online at http:// www.cell.com/cancer-cell/supplemental/S1535-6108(09)00079-8.
